CA3254814A1 - Pharmaceutical compositions of recombinant human acid sphingomyelinase and processes - Google Patents

Pharmaceutical compositions of recombinant human acid sphingomyelinase and processes

Info

Publication number
CA3254814A1
CA3254814A1 CA3254814A CA3254814A CA3254814A1 CA 3254814 A1 CA3254814 A1 CA 3254814A1 CA 3254814 A CA3254814 A CA 3254814A CA 3254814 A CA3254814 A CA 3254814A CA 3254814 A1 CA3254814 A1 CA 3254814A1
Authority
CA
Canada
Prior art keywords
compositions
methods
recombinant human
human acid
acid sphingomyelinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3254814A
Other languages
English (en)
French (fr)
Inventor
Thomas M. Wasylenko
Kevin Brower
Xiaoying Jin
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CA3254814A1 publication Critical patent/CA3254814A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3254814A 2022-03-18 2023-03-17 Pharmaceutical compositions of recombinant human acid sphingomyelinase and processes Pending CA3254814A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263321636P 2022-03-18 2022-03-18
US63/321,636 2022-03-18
PCT/US2023/064657 WO2023178325A1 (en) 2022-03-18 2023-03-17 Pharmaceutical recombinant human acid sphingomyelinase compositions and methods

Publications (1)

Publication Number Publication Date
CA3254814A1 true CA3254814A1 (en) 2023-09-21

Family

ID=86051983

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3254814A Pending CA3254814A1 (en) 2022-03-18 2023-03-17 Pharmaceutical compositions of recombinant human acid sphingomyelinase and processes

Country Status (12)

Country Link
US (1) US20230365946A1 (cg-RX-API-DMAC7.html)
EP (1) EP4493684A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509722A (cg-RX-API-DMAC7.html)
KR (1) KR20240156645A (cg-RX-API-DMAC7.html)
CN (1) CN119365593A (cg-RX-API-DMAC7.html)
AR (1) AR128825A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023235321A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254814A1 (cg-RX-API-DMAC7.html)
IL (1) IL315655A (cg-RX-API-DMAC7.html)
MX (1) MX2024011382A (cg-RX-API-DMAC7.html)
TW (1) TW202403043A (cg-RX-API-DMAC7.html)
WO (1) WO2023178325A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119968454A (zh) 2022-09-28 2025-05-09 建新公司 用于生产生物产品的系统和装置及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US20020137173A1 (en) * 2001-02-05 2002-09-26 Dae-Kyong Kim Membrane-associated sphingomyelinase derived from bovine brain, isolation method therefor and anti-sphingomyelinase monoclonal anitibody
BRPI0411291A (pt) * 2003-06-12 2006-08-01 Genzyme Corp esfingomielinase acida humana modificada tendo atividade aumentada e métodos para a fabricação da mesma
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
CN101918430A (zh) 2008-01-18 2010-12-15 弗·哈夫曼-拉罗切有限公司 非糖基化蛋白质的纯化
KR20130020789A (ko) 2010-05-19 2013-02-28 에프. 호프만-라 로슈 아게 소수성 상호작용 크로마토그래피 방법
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US10259842B2 (en) 2013-05-15 2019-04-16 Medimmune, Llc Purification of recombinantly produced polypeptides
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy
EP3728287B1 (en) 2017-12-19 2024-04-10 CSL Behring Lengnau AG Protein purification and virus inactivation with alkyl glycosides
PY1939780A (es) 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida

Also Published As

Publication number Publication date
TW202403043A (zh) 2024-01-16
KR20240156645A (ko) 2024-10-30
WO2023178325A1 (en) 2023-09-21
AU2023235321A1 (en) 2024-10-31
MX2024011382A (es) 2024-09-23
CN119365593A (zh) 2025-01-24
EP4493684A1 (en) 2025-01-22
JP2025509722A (ja) 2025-04-11
IL315655A (en) 2024-11-01
US20230365946A1 (en) 2023-11-16
AR128825A1 (es) 2024-06-19

Similar Documents

Publication Publication Date Title
EP4291225A4 (en) RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE AND USES THEREOF
EP4114430A4 (en) TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS
PL4247335T3 (pl) Kompozycja farmaceutyczna zawierająca kannabidiol i kwas hialuronowy
IL316170A (en) Pharmaceutical compositions of therapeutic proteins and methods of use
IL315655A (en) Pharmaceutical compositions of human recombinant acid sphingomyelinase and methods
CA3260120A1 (en) COLLAGEN PEPTIDE-BASED DRUG COMPOSITIONS AND THEIR USES
HK40120786A (en) Pharmaceutical recombinant human acid sphingomyelinase compositions and methods
CA3266804A1 (en) PHARMACEUTICAL COMPOSITION AND ITS USE
CA3262492A1 (en) Formulations containing G-CSF and their uses
CA3265143A1 (en) Orodispersible pharmaceutical composition of fexofenadine and its preparation process
EP4213876A4 (en) PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE AND A PROTEIN
HK40105005A (en) Recombinant human acid alpha-glucosidase and uses thereof
EP4245768A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING A VARIANT OF HUMAN INTERLEUKIN 2 OR A DERIVATIVE THEREOF AND ITS USE
CA3304242A1 (en) Pharmaceutical formulations comprising 5-meo-dmt and their therapeutic uses
HK40122888A (en) Pharmaceutical formulations of bictegravir and lenacapavir
GB202408903D0 (en) Pharmaceutical compositions and medical uses
HK40131600A (en) Pharmaceutical formulations and uses thereof
CA3300004A1 (en) Pharmaceutical formulations of bictegravir and lenacapavir
AU2024902868A0 (en) Pharmaceutical Formulations and Uses Thereof
CA3298458A1 (en) Pharmaceutical formulations for inhalation and uses thereof
AU2025901328A0 (en) Pharmaceutical compositions and methods
CA3304568A1 (en) Pharmaceutical compositions comprising maralixibat and uses thereof
AU2024901720A0 (en) Pharmaceutical compositions and methods
AU2023902710A0 (en) Pharmaceutical compositions and methods
AU2022903010A0 (en) Pharmaceutical compositions and methods

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240910

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241111

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250212

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250212

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250506

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250606

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260306

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260306

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20260314

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20260314

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260528